IO Biotech, Inc. (IOBT): Price and Financial Metrics
GET POWR RATINGS... FREE!
IOBT Stock Price Chart Interactive Chart >
IOBT Price/Volume Stats
|Current price||$4.55||52-week high||$17.88|
|Prev. close||$4.85||52-week low||$3.56|
|Day high||$4.88||Avg. volume||33,400|
|50-day MA||$6.52||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||131.11M|
IO Biotech, Inc. (IOBT) Company Bio
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death ligand (PD-L1). It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. IO Biotech, Inc. was incorporated in 2021 and is based in Copenhagen, Denmark.
Most Popular Stories View All
IOBT Latest News Stream
|Loading, please wait...|
IOBT Latest Social Stream
View Full IOBT Social Stream
Latest IOBT News From Around the Web
Below are the latest news stories about IO Biotech Inc that investors may wish to consider to help them evaluate IOBT as an investment opportunity.
If you want to know who really controls IO Biotech, Inc. ( NASDAQ:IOBT ), then you'll have to look at the makeup of its...
- Solidified Nasdaq position as the leading European listings hub with 219 new equity listings, including a record number of 174 initial public offerings (IPOs), raising a total of EUR 13.4 billion- Retail inflow and large interest in SME trading spurred all-time high levels in equity and derivative trading- Continued to lead in ESG with venture investment in Puro.earth and new product launches STOCKHOLM, Sweden, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) announced today that Nasdaq
Publication of Phase 1/2 MM1636 Trial Results Follows FDA Breakthrough Therapy Designation for IO102-IO103 in combination with an anti-PD-1 monoclonal antibody Publication of Phase 1/2 MM1636 Trial Results Follows FDA Breakthrough Therapy Designation for IO102-IO103 in combination with an anti-PD-1 monoclonal antibody
No summary available.
IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial
IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor typesNEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it has entered into a third clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and C
IOBT Price Returns